Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects, good and/or bad, the combination of
sorafenib and everolimus will have on your thyroid cancer. Treatment guidelines from the
National Comprehensive Cancer Network include sorafenib as a treatment option for thyroid
cancer. Sorafenib is pill that is approved by the FDA for the treatment of kidney and liver
cancers. Sorafenib may work in many different ways. It helps decrease the blood supply to
tumors. By doing so, it may limit the tumor's source of oxygen and nutrients and prevent the
tumor from growing. Everolimus is an oral medication that is FDA approved for the treatment
of kidney cancer. It inhibits a protein kinase called mTOR ("mammalian Target of Rapamycin").
In laboratory studies, the addition of everolimus to sorafenib works better than sorafenib
alone. These two drugs are being used together to treat other types of cancer in other
clinical studies. In addition, the cancer will be evaluated to help us find factors that can
help predict who would benefit most from this combination of drugs.